shutterstock_1569668848_sundry_photography
Sundry Photography / Shutterstock.com
16 December 2019AmericasRory O'Neill

Senators demand USPTO probe into Gilead allegations

The US Patent and Trademark Office (USPTO) is coming under increasing pressure to review allegations that Gilead delayed development of its latest HIV drug in order to maximise profits.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
26 May 2026   Two days of discussions at LSPN North America revealed an industry grappling with narrower patent claims, global strategy changes, AI disruption and tougher dealmaking conditions.
Americas
26 May 2026   Ahead of WIPR Trade Secrets West, Cooley partner Heidi Keefe says that for legal teams, caution—not business pressure—should be the priority.
Americas
22 May 2026   A US appeals court has handed the generic drugmaker victory in a closely watched dispute over a treatment for a serious inherited kidney condition, dealing a setback to its branded rival.